Skip to main content
. Author manuscript; available in PMC: 2018 May 15.
Published in final edited form as: Cancer Res. 2017 Mar 31;77(10):2607–2619. doi: 10.1158/0008-5472.CAN-16-2534

Figure 5. – Combining low dose IPI-145 with PD-L1 blockade results in enhanced control of MOC1 tumors.

Figure 5

Mice bearing palpable MOC1 tumors were treated with 15 mg/kg IPI-145 (daily × 14 days) and PD-L1 mAb (200 μg/injection × 3) alone or in combination and mice were followed for tumor growth and survival (n=8–10 mice/group). A, primary tumor growth summary curves during treatment and in the immediate post-treatment period (Tukey’s multiple comparisons analysis). B, survival analysis. C, individual growth curves (in color) compared to control (black) demonstrating long-term growth kinetics for each experimental condition. IPI-145 treatment indicated below x-axis, black arrows indicate PD-L1 mAb treatments. *, p<0.05; **, p<0.01; ***, p<0.001.